We previously reported (J Clin Oncol 28:4492-4499, 2010) an overall survival (OS) of 66% at 1 year and 54% at 3 years after allogeneic hematopoietic cell transplantation (HCT) in patients with advanced-stage mycosis fungoides and Sezary syndrome (MF/SS). Here, we present an extended analysis of this experience, with a median follow-up in survivors of 7 years (longest follow-up: 12 years; interquartile range: 6 to 9 years). Our data show that patients with advanced-stage MF/SS continue to benefit from allogeneic HCT over time, with an OS of 46% at 5 years and 44% at 7 years (95% CI, 35% to 61% and 33% to 59%, respectively), and a PFS of 32% at 5 years and 30% at 7 years (95% CI, 22% to 47% and 20% to 45%, respectively). Our results, from the largest series on this topic published to date, now updated with a prolonged median follow-up of 7 years, provide a clearer picture of the value of allogeneic HCT as a therapeutic strategy for high-risk patients with advanced-stage MF/SS and further support the existence of a clinically relevant and persistent graft-versus-MF/SS effect.

Long-term outcome of allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and sézary syndrome: A European society for blood and marrow transplantation lymphoma working party extended analysis / Duarte, Rafael F; Boumendil, Ariane; Onida, Francesco; Gabriel, Ian; Arranz, Reyes; Arcese, William; Poiré, Xavier; Kobbe, Guido; Narni, Franco; Cortelezzi, Agostino; Olavarría, Eduardo; Schmitz, Norbert; Sureda, Anna; Dreger, Peter. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - STAMPA. - 32:(2014), pp. 3347-3348. [10.1200/JCO.2014.57.5597]

Long-term outcome of allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and sézary syndrome: A European society for blood and marrow transplantation lymphoma working party extended analysis

NARNI, Franco;
2014-01-01

Abstract

We previously reported (J Clin Oncol 28:4492-4499, 2010) an overall survival (OS) of 66% at 1 year and 54% at 3 years after allogeneic hematopoietic cell transplantation (HCT) in patients with advanced-stage mycosis fungoides and Sezary syndrome (MF/SS). Here, we present an extended analysis of this experience, with a median follow-up in survivors of 7 years (longest follow-up: 12 years; interquartile range: 6 to 9 years). Our data show that patients with advanced-stage MF/SS continue to benefit from allogeneic HCT over time, with an OS of 46% at 5 years and 44% at 7 years (95% CI, 35% to 61% and 33% to 59%, respectively), and a PFS of 32% at 5 years and 30% at 7 years (95% CI, 22% to 47% and 20% to 45%, respectively). Our results, from the largest series on this topic published to date, now updated with a prolonged median follow-up of 7 years, provide a clearer picture of the value of allogeneic HCT as a therapeutic strategy for high-risk patients with advanced-stage MF/SS and further support the existence of a clinically relevant and persistent graft-versus-MF/SS effect.
32
3347
3348
Long-term outcome of allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and sézary syndrome: A European society for blood and marrow transplantation lymphoma working party extended analysis / Duarte, Rafael F; Boumendil, Ariane; Onida, Francesco; Gabriel, Ian; Arranz, Reyes; Arcese, William; Poiré, Xavier; Kobbe, Guido; Narni, Franco; Cortelezzi, Agostino; Olavarría, Eduardo; Schmitz, Norbert; Sureda, Anna; Dreger, Peter. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - STAMPA. - 32:(2014), pp. 3347-3348. [10.1200/JCO.2014.57.5597]
Duarte, Rafael F; Boumendil, Ariane; Onida, Francesco; Gabriel, Ian; Arranz, Reyes; Arcese, William; Poiré, Xavier; Kobbe, Guido; Narni, Franco; Cortelezzi, Agostino; Olavarría, Eduardo; Schmitz, Norbert; Sureda, Anna; Dreger, Peter
File in questo prodotto:
File Dimensione Formato  
Narni JCO 2014.pdf

non disponibili

Descrizione: articolo
Tipologia: Versione pubblicata dall'editore
Dimensione 67.25 kB
Formato Adobe PDF
67.25 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1077346
Citazioni
  • ???jsp.display-item.citation.pmc??? 16
  • Scopus 67
  • ???jsp.display-item.citation.isi??? 59
social impact